Home › Immuunsysteem en aandoeningen › New York › New York City
Immuunsysteem en aandoeningen klinische studies in New York City, NY
12 studies voor Immuunsysteem en aandoeningen zoeken deelnemers op locaties in en rond New York City (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RekruterenFase 1
- Memorial Sloan Kettering Cancer Center, New York
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruterenFase 3
- Memorial Sloan Kettering Cancer Center, New York
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
RekruterenFase 3
- Memorial Sloan Kettering Cancer Center, New York
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruterenFase 1/2
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Abatacept for the Treatment of Giant Cell Arteritis
RekruterenFase 3
- Hospital for Special Surgery, New York
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RekruterenFase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RekruterenFase 2
- Inmagene Site 21, New York
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RekruterenFase 2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
RekruterenFase 2
- Columbia University Irving Medical Center, New York
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RekruterenFase 1/2
- Columbia University, New York
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RekruterenFase 1/2
- Mt Sinai, New York
- Memorial Sloan Kettering Cancer Center, New York
Biologics And Clinical Immunology Cohort at Sinai
RekruterenObservatieonderzoek
- Mount Sinai, New York
Immuunsysteem en aandoeningen studies in andere steden
- Washington, DC13 studies
- Philadelphia, PA10 studies
- Boston, MA10 studies
- Atlanta, GA9 studies
- Portland, OR9 studies
- Houston, TX9 studies
- Los Angeles, CA8 studies
- Cleveland, OH8 studies
- Chicago, IL8 studies
- Milwaukee, WI6 studies
- Seattle, WA6 studies
- Cedar Rapids, IA6 studies
Andere studies in New York City
- Borstkanker136 studies
- Niet-kleincellige longkanker121 studies
- Kanker (alle vormen)109 studies
- Prostaatkanker103 studies
- Metastatische kanker93 studies
- Colorectale kanker78 studies
- Eierstokkanker69 studies
- Longkanker60 studies
- Multipel myeloom60 studies
- Aldermeesklierkanker60 studies
- Endometriumkanker52 studies
- Acute myeloïde leukemie51 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.